Project Grant R41CA257020

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The Tiny Cargo Company received a $432,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant to test the scalability of an exosome isolation technology for developing an orally administered radioprotective therapeutic. The goal is to establish proof-of-concept for a safe, orally delivered drug platform capable of transporting biologic and small molecule therapeutics to treat radiation damage and related diseases. The first year of the award will determine scaling...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Absco Therapeutics, Inc. (DBA Abscotx) to develop an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors. The project aims to create an innovative drug delivery platform that can improve the efficacy and safety of biologic cancer therapies, addressing challenges such as poor on-target...

This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...

Federal Project Grant Award Summary Round Table Research, Inc. (RTR), in collaboration with researchers at the University of North Carolina at Chapel Hill, received a $305,031 Phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025 through August 31, 2026. The award funds the advancement of engineered extracellular vesicle (EV) therapy toward pre-Investigational New...

Federal Project Grant Award Summary Gigamune, Inc. received an $800,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on September 15, 2025, with a completion date of August 31, 2026. Under this award, the company, led by Principal Investigator David Scott Johnson, Ph.D., is developing a novel lentiviral vector platform for enhanced in vivo delivery of T cell receptors (TCRs) as a cell therapy approach for Stage IV...

This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...

Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...